Modeling the economic benefits of an AIDS vaccine

David Bishai, Maria K. Lin, C. W.B. Kiyonga

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Economic models were used to describe the potential for an AIDS vaccine to prevent medical spending and lost productivity throughout the world. In terms of avoided medical spending, preventing 75% of the AIDS risk for 10 years in one adult male is estimated to be worth US$ 343 in western Europe, US$ 4.59 in south and SE Asia, and US$ 2.67 in sub-Saharan Africa. The expected medical savings from a 75% effective vaccine would exceed US$ 25.00 per person for over 700 million people. Although an AIDS vaccine would save more lives in poverty stricken areas, it would save more money in developed countries. The mismatch between the public health needs and market forces is highlighted by this model.

Original languageEnglish (US)
Pages (from-to)526-531
Number of pages6
Issue number3-4
StatePublished - Nov 12 2001


  • AIDS
  • Costs
  • Demand
  • Economics
  • Epidemiology
  • HIV
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Modeling the economic benefits of an AIDS vaccine'. Together they form a unique fingerprint.

Cite this